Personnel de recherche : Questions médicales fréquentes
Nom anglais: Research Personnel
Descriptor UI:D012108
Tree Number:M01.526.839
Termes MeSH sélectionnés :
Interrupted Time Series Analysis
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Personnel de recherche : Questions médicales les plus fréquentes",
"headline": "Personnel de recherche : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Personnel de recherche : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-07",
"dateModified": "2025-04-01",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Personnel de recherche"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Groupes professionnels",
"url": "https://questionsmedicales.fr/mesh/D009274",
"about": {
"@type": "MedicalCondition",
"name": "Groupes professionnels",
"code": {
"@type": "MedicalCode",
"code": "D009274",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "M01.526"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Personnel de recherche",
"alternateName": "Research Personnel",
"code": {
"@type": "MedicalCode",
"code": "D012108",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "I L Krom",
"url": "https://questionsmedicales.fr/author/I%20L%20Krom",
"affiliation": {
"@type": "Organization",
"name": "The Federal State Budget Educational Institution of Higher Education \"The V. I. Razumovsky Saratov State Medical University\" of Minzdrav of Russia, 410012, Saratov, Russia, irina.crom@yandex.ru."
}
},
{
"@type": "Person",
"name": "M V Erugina",
"url": "https://questionsmedicales.fr/author/M%20V%20Erugina",
"affiliation": {
"@type": "Organization",
"name": "The Federal State Budget Educational Institution of Higher Education \"The V. I. Razumovsky Saratov State Medical University\" of Minzdrav of Russia, 410012, Saratov, Russia."
}
},
{
"@type": "Person",
"name": "Luellen Fletcher",
"url": "https://questionsmedicales.fr/author/Luellen%20Fletcher",
"affiliation": {
"@type": "Organization",
"name": "Perelman School of Medicine Path BioResource University of Pennsylvania M163 John Morgan Bldg., 3620 Hamilton WalkPhiladelphiaPennsylvania19104 USA."
}
},
{
"@type": "Person",
"name": "Christina A Harrington",
"url": "https://questionsmedicales.fr/author/Christina%20A%20Harrington",
"affiliation": {
"@type": "Organization",
"name": "University Shared Resources and Knight Cancer Institute Oregon Health & Science University 3181 S.W. Sam Jackson Park RoadPortlandOregon97239 USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The Influence of the Great Recession on Adolescent Major Depressive Episodes and Treatment in the United States: An Interrupted Time Series Analysis.",
"datePublished": "2023-10-11",
"url": "https://questionsmedicales.fr/article/37831049",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jadohealth.2023.08.023"
}
},
{
"@type": "ScholarlyArticle",
"name": "The effectiveness of pay-for-performance contracts with non-governmental organizations in Afghanistan - results of a controlled interrupted time series analysis.",
"datePublished": "2023-02-07",
"url": "https://questionsmedicales.fr/article/36750963",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12913-023-09099-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "The impact of systematically repairing multiple choice questions with low discrimination on assessment reliability: an interrupted time series analysis.",
"datePublished": "2024-07-12",
"url": "https://questionsmedicales.fr/article/39114792",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.36834/cmej.77596"
}
},
{
"@type": "ScholarlyArticle",
"name": "Potential impact of blood cholesterol guidelines on statin treatment in the U.S. population using interrupted time series analysis.",
"datePublished": "2024-05-10",
"url": "https://questionsmedicales.fr/article/38730371",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12872-024-03921-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Assessing the impact of the \"malaria supporters project\" intervention to malaria control in the Brazilian Amazon: an interrupted time-series analysis.",
"datePublished": "2023-09-16",
"url": "https://questionsmedicales.fr/article/37715245",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12936-023-04706-z"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Personnes",
"item": "https://questionsmedicales.fr/mesh/D009272"
},
{
"@type": "ListItem",
"position": 3,
"name": "Groupes professionnels",
"item": "https://questionsmedicales.fr/mesh/D009274"
},
{
"@type": "ListItem",
"position": 4,
"name": "Personnel de recherche",
"item": "https://questionsmedicales.fr/mesh/D012108"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Personnel de recherche - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Personnel de recherche",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Personnel de recherche",
"description": "Comment évaluer l'efficacité d'un traitement ?\nQuelles méthodes de recherche sont utilisées ?\nComment identifier les biais dans une étude ?\nQu'est-ce qu'une revue systématique ?\nComment mesurer la validité d'un test ?",
"url": "https://questionsmedicales.fr/mesh/D012108?mesh_terms=Interrupted+Time+Series+Analysis&page=6#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Personnel de recherche",
"description": "Quels symptômes surveiller lors d'une étude ?\nComment évaluer les effets secondaires ?\nQuels indicateurs de santé sont mesurés ?\nComment documenter les symptômes des participants ?\nQuelle est l'importance des auto-évaluations ?",
"url": "https://questionsmedicales.fr/mesh/D012108?mesh_terms=Interrupted+Time+Series+Analysis&page=6#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Personnel de recherche",
"description": "Quelles stratégies de prévention sont utilisées ?\nComment évaluer l'impact des programmes de prévention ?\nQuels facteurs influencent la prévention ?\nComment sensibiliser à la prévention ?\nQuelle est l'importance du dépistage précoce ?",
"url": "https://questionsmedicales.fr/mesh/D012108?mesh_terms=Interrupted+Time+Series+Analysis&page=6#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Personnel de recherche",
"description": "Comment choisir un traitement dans une étude ?\nQuelles sont les approches de traitement courantes ?\nComment évaluer l'adhérence au traitement ?\nQuels sont les critères d'évaluation des traitements ?\nComment gérer les traitements combinés ?",
"url": "https://questionsmedicales.fr/mesh/D012108?mesh_terms=Interrupted+Time+Series+Analysis&page=6#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Personnel de recherche",
"description": "Quelles complications peuvent survenir dans les études ?\nComment gérer les complications dans une étude ?\nQuels sont les risques associés aux traitements ?\nComment évaluer les complications post-traitement ?\nQuelle est l'importance de la déclaration des complications ?",
"url": "https://questionsmedicales.fr/mesh/D012108?mesh_terms=Interrupted+Time+Series+Analysis&page=6#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Personnel de recherche",
"description": "Quels sont les facteurs de risque courants ?\nComment identifier les facteurs de risque dans une étude ?\nQuel rôle joue l'environnement dans les risques ?\nComment évaluer l'impact des facteurs de risque ?\nQuelle est l'importance de la prévention des risques ?",
"url": "https://questionsmedicales.fr/mesh/D012108?mesh_terms=Interrupted+Time+Series+Analysis&page=6#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer l'efficacité d'un traitement ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par des études cliniques contrôlées et des analyses statistiques."
}
},
{
"@type": "Question",
"name": "Quelles méthodes de recherche sont utilisées ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les méthodes incluent les essais randomisés, les études de cohorte et les méta-analyses."
}
},
{
"@type": "Question",
"name": "Comment identifier les biais dans une étude ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les biais peuvent être identifiés par l'examen des méthodes de sélection et d'analyse des données."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'une revue systématique ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est une synthèse des études existantes sur un sujet, évaluant la qualité des preuves."
}
},
{
"@type": "Question",
"name": "Comment mesurer la validité d'un test ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La validité est mesurée par la sensibilité, la spécificité et la valeur prédictive."
}
},
{
"@type": "Question",
"name": "Quels symptômes surveiller lors d'une étude ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient selon l'étude, mais incluent souvent douleur, fatigue et dysfonction."
}
},
{
"@type": "Question",
"name": "Comment évaluer les effets secondaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires sont évalués par des questionnaires et des rapports de patients."
}
},
{
"@type": "Question",
"name": "Quels indicateurs de santé sont mesurés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les indicateurs incluent la pression artérielle, le taux de cholestérol et les marqueurs biologiques."
}
},
{
"@type": "Question",
"name": "Comment documenter les symptômes des participants ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes sont documentés par des journaux de santé et des évaluations cliniques régulières."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance des auto-évaluations ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les auto-évaluations fournissent des informations précieuses sur l'état de santé perçu par le patient."
}
},
{
"@type": "Question",
"name": "Quelles stratégies de prévention sont utilisées ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les stratégies incluent l'éducation, les vaccinations et les dépistages réguliers."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'impact des programmes de prévention ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'impact est évalué par des études de suivi et des analyses de données de santé publique."
}
},
{
"@type": "Question",
"name": "Quels facteurs influencent la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'accès aux soins, le niveau d'éducation et les comportements de santé."
}
},
{
"@type": "Question",
"name": "Comment sensibiliser à la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "La sensibilisation se fait par des campagnes d'information, des ateliers et des médias sociaux."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance du dépistage précoce ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le dépistage précoce permet d'identifier les maladies à un stade précoce, améliorant les résultats."
}
},
{
"@type": "Question",
"name": "Comment choisir un traitement dans une étude ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le choix est basé sur des critères d'inclusion, des protocoles et des résultats antérieurs."
}
},
{
"@type": "Question",
"name": "Quelles sont les approches de traitement courantes ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les approches incluent la pharmacothérapie, la thérapie physique et les interventions chirurgicales."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'adhérence au traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'adhérence est évaluée par des questionnaires, des entretiens et des suivis réguliers."
}
},
{
"@type": "Question",
"name": "Quels sont les critères d'évaluation des traitements ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères incluent l'efficacité, la sécurité, la tolérance et la qualité de vie."
}
},
{
"@type": "Question",
"name": "Comment gérer les traitements combinés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements combinés nécessitent une évaluation rigoureuse des interactions et des effets cumulés."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir dans les études ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des effets indésirables, des non-conformités et des biais d'étude."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications dans une étude ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique une surveillance étroite, des ajustements de protocole et des rapports transparents."
}
},
{
"@type": "Question",
"name": "Quels sont les risques associés aux traitements ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des réactions allergiques, des interactions médicamenteuses et des complications chirurgicales."
}
},
{
"@type": "Question",
"name": "Comment évaluer les complications post-traitement ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont évaluées par des suivis cliniques et des questionnaires de satisfaction."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la déclaration des complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La déclaration permet d'améliorer la sécurité des patients et d'affiner les protocoles de recherche."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque courants ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, le sexe, les antécédents médicaux et les habitudes de vie."
}
},
{
"@type": "Question",
"name": "Comment identifier les facteurs de risque dans une étude ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs sont identifiés par des questionnaires, des entretiens et des analyses de données."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'environnement dans les risques ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'environnement influence les risques par l'exposition à des toxines, des infections et des comportements."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'impact des facteurs de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'impact est évalué par des études épidémiologiques et des analyses statistiques."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la prévention des risques ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention réduit l'incidence des maladies et améliore la santé publique globale."
}
}
]
}
]
}
In the United States, adolescent depression increased beginning in 2008-2010, coinciding with the Great Recession. We investigated whether this time of changing economic circumstances impacted adolesc...
We analyzed data for adolescents aged 12-17 years from the 2004-2019 National Survey on Drug Use and Health (N = 256,572). Adolescents' past-year major depressive episodes (MDEs) were measured by self...
The Great Recession was not associated with an immediate increase in MDE prevalence (β:-0.77 [i.e., quarter-year change in prevalence], 95% confidence interval (CI): -2.23, 0.69). However, the increas...
The Great Recession was not associated with increased adolescent depression prevalence, although there was an acceleration in the trend of adolescent MDE following the recession. The prevalence of MDE...
In many contexts, including fragile settings like Afghanistan, the coverage of basic health services is low. To address these challenges there has been considerable interest in working with NGOs and e...
We conducted an interrupted time series (ITS) analysis with a non-randomized comparison group that employed segmented regression models and used independently verified health management information sy...
Independent verification of the HMIS data found that consistency and accuracy was greater than 90% in the contracted provinces. The introduction of P4P increased the 10 P4P-compensated service deliver...
P4P contracts with NGOs led to a substantial improvement in service delivery at lower cost despite a very difficult security situation. The promising results from this large-scale experience warrant m...
At our centre, we introduced a continuous quality improvement (CQI) initiative during academic year 2018-19 targeting for repair multiple choice question (MCQ) items with discrimination index (...
The 2013 ACC/AHA Guideline was a paradigm shift in lipid management and identified the four statin-benefit groups. Many have studied the guideline's potential impact, but few have investigated its pot...
To evaluate the potential (long-term) impact of the 2013 ACC/AHA Guideline release in Nov 2013 in the U.S., we investigated the association of the 2013 ACC/AHA Guideline with the trend changes in 5-Ye...
197,021 patients were included (ASCVD: 19,060; High-LDL: 33,907; Diabetes: 138,159; High-ASCVD-Risk: 5,895). After the guideline release, the long-term trend (slope) of 5-Year MACE Survival for the Di...
The 2013 ACA/AHA Guideline release is associated with trend improvements in the long-term MACE Survival for Diabetes group and optimal statin use for ASCVD group. These significant associations might ...
In 2021, Brazil was responsible for more than 25% of malaria cases in the Americas. Although the country has shown a reduction of cases in the last decades, in 2021 it reported over 139,000 malaria ca...
An ecological time-series analysis was conducted to assess the "Malaria Supporters Project" effect. The study used data on Annual Parasitic Incidence (API) spanning the period from 2003 to 2020 across...
The intervention group registered 1,104,430 cases between 2012 and 2020, a 50.6% reduction compared to total cases between 2003 and 2011. In 2020 there were 95,621 cases, 50.4% fewer than in 2011. The...
The intervention is not a silver bullet to control malaria, but it has reduced API in locations with high malaria endemicity. Furthermore, the model has the potential to be replicated in other countri...
Access to healthcare services is important, especially for patients with chronic diseases. We evaluated the effect of the COVID-19 pandemic on outpatient visits and medication for patients with hypert...
Nationwide claims data were extracted for patients with hypertension and diabetes from January 2019 to July 2020. We used an interrupted time series (ITS) analysis to evaluate the pandemic's impact on...
The number of outpatient visits for diabetes significantly declined in February 2020, when community transmission began. However, when high-intensity social distancing was relaxed in April 2020, outpa...
Outpatient visits decreased immediately when COVID-19 spread to local communities. However, the number of days of medication supplied per visit increased to compensate for the longer intervals between...
The overload of health services because of the COVID-19 pandemic has reduced the population's access to treatment and prevention of other diseases. This study aimed to identify whether there was a cha...
This was an ecological time series study of mammograms and breast biopsies in women aged 30 years or older from an open-access data set of the Public Health System of Brazil from 2017 to July 2021....
In 2020, there was a reduction of -40.9% in mammograms and -7.9% in breast biopsies compared with the prepandemic period. From 2017 to 2020, there was an increase in the breast biopsies ratio per mamm...
The COVID-19 pandemic harmed the increasing trend of breast biopsies, their total direct costs, BI-RADS 0 to III and IV to V mammograms, observed in the prepandemic period. Furthermore, there was a te...
To study the use of a quasi-experimental design to assess the effects of scaling reimbursement policies on the incidence of chronic-periodontitis procedures....
Interrupted time series analysis was used to compare the effects before and after policy implementation using data on the number of periodontitis-related procedures from the Korean National Health Ins...
Following the policy implementation from July 2013, an immediate increase was observed in total and basic procedures. No significant changes were noted in intermediate and advanced procedures initiall...
Following the new policy implementation, the number of intermediate procedures decreased while the number of advanced procedures increased, especially among patients with comorbidities. These findings...
Prescription opioids were a major initial driver of the opioid crisis. States have attempted to reduce overprescribing by enacting policies that limit opioid prescriptions, but the impacts of such pol...
To examine the association of implementation of a state prescribing limits policy with opioid prescribing and transitions to long-term opioid use....
Interrupted time series analyses assessing trends in new opioid prescriptions and long-term use before and after policy implementation....
A total of 130,591 New Jersey Medicaid enrollees ages 18-64 who received an initial opioid prescription from January 2014 to December 2019....
New Jersey's opioid prescribing limit policy implemented in March 2017....
Total new opioid prescriptions, percentage of new prescriptions with >5 days' supply, and transition to long-term opioid use, defined as having opioid supply on day 90 after the initial prescription....
Policy implementation was associated with a significant monthly increase in new opioid prescriptions of 0.86 per 10,000 enrollees, halving the pre-policy decline in the prescribing rate. Among new opi...
The New Jersey policy was associated with a reduction in initial prescriptions with >5 days' supply, but not with an overall decline in new opioid prescriptions or in the rate at which initial prescri...
To assess emergency department (ED) presentation numbers in Queensland during the coronavirus disease 2019 (COVID-19) pandemic to mid-2021, a period of relatively low COVID-19 case numbers....
Interrupted time series analysis....
All 105 Queensland public hospital EDs....
Numbers of ED presentations during the COVID-19 lockdown period (11 March 2020 - 30 June 2020) and the period of easing restrictions (1 July 2020 - 30 June 2021), compared with pre-pandemic period (1 ...
During the lockdown period, the mean number of ED presentations was 19.4% lower (95% confidence interval, -20.9% to -17.9%) than during the pre-pandemic period (predicted mean number: 5935; actual num...
The COVID-19 pandemic and related public restrictions were associated with profound changes in health care use. Pandemic plans should include advice about continuing to seek care for serious health co...